Combination therapy development: strategic directions towards improving current I-O response rates

IMMUNO-ONCOLOGY INSIGHTS

May 2022

Combination therapy development: strategic directions towards improving current I-O response rates

Foreword

Spotlight on combination therapy development: strategic directions towards improving current I-O response rates

Spotlight on combination therapy development: strategic directions towards improving current I-O response rates

Adil Daud, Alexandra Haugh, Saya Jacob

Expert Insight

Site specific responses to immune checkpoint inhibitors

Site specific responses to immune checkpoint inhibitors

Clinton Wu, Adil Daud

Implications of liver metastasis for cancer immunotherapy

Implications of liver metastasis for cancer immunotherapy

Combination immune therapy in melanoma: a tale of two therapies

Combination immune therapy in melanoma: a tale of two therapies

Gregory A Daniels

Commentary

A winning combination in the war against deadly cancers: exploring new opportunities for combining antibody–drug conjugates and cancer immunotherapies

A winning combination in the war against deadly cancers: exploring new opportunities for combining antibody–drug conjugates and cancer immunotherapies

Interview

The evolution of combination immunotherapy: current successes & future goals

The evolution of combination immunotherapy: current successes & future goals

Better by design: a regulatory perspective on rationalizing combination selection and development

Better by design: a regulatory perspective on rationalizing combination selection and development

28 February 2022

Viewpoint

Update on antibody–drug conjugates: where are we now, & where are we going?

Update on antibody–drug conjugates: where are we now, & where are we going?

Fernanda Arnaldez